Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes.
Identifieur interne : 000383 ( PubMed/Curation ); précédent : 000382; suivant : 000384Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes.
Auteurs : S. Sambhara ; S. Woods ; R. Arpino ; A. Kurichh ; A. Tamane ; B. Underdown ; M. Klein ; K. Lövgren Bengtsson ; B. Morein ; D. BurtSource :
- The Journal of infectious diseases [ 0022-1899 ] ; 1998.
Descripteurs français
- KwdFr :
- Animaux, Complexes immunostimulants, Facteurs temps, Femelle, Infections à Orthomyxoviridae (), Infections à Orthomyxoviridae (immunologie), Infections à Orthomyxoviridae (mortalité), Lymphocytes T cytotoxiques (immunologie), Relation dose-effet des médicaments, Réactions croisées, Souris, Souris de lignée BALB C, Vaccins antigrippaux, Virion (immunologie), Virus de la grippe A (), Virus de la grippe A (immunologie).
- MESH :
- immunologie : Infections à Orthomyxoviridae, Lymphocytes T cytotoxiques, Virion, Virus de la grippe A.
- mortalité : Infections à Orthomyxoviridae.
- Animaux, Complexes immunostimulants, Facteurs temps, Femelle, Infections à Orthomyxoviridae, Relation dose-effet des médicaments, Réactions croisées, Souris, Souris de lignée BALB C, Vaccins antigrippaux, Virus de la grippe A.
English descriptors
- KwdEn :
- Animals, Cross Reactions, Dose-Response Relationship, Drug, Female, ISCOMs, Influenza A virus (classification), Influenza A virus (immunology), Influenza Vaccines, Mice, Mice, Inbred BALB C, Orthomyxoviridae Infections (immunology), Orthomyxoviridae Infections (mortality), Orthomyxoviridae Infections (prevention & control), T-Lymphocytes, Cytotoxic (immunology), Time Factors, Virion (immunology).
- MESH :
- chemical : ISCOMs, Influenza Vaccines.
- classification : Influenza A virus.
- immunology : Influenza A virus, Orthomyxoviridae Infections, T-Lymphocytes, Cytotoxic, Virion.
- mortality : Orthomyxoviridae Infections.
- prevention & control : Orthomyxoviridae Infections.
- Animals, Cross Reactions, Dose-Response Relationship, Drug, Female, Mice, Mice, Inbred BALB C, Time Factors.
Abstract
Influenza immunostimulating complexes (flu-ISCOMs) and a monovalent subvirion vaccine prepared with an H1N1 strain of influenza virus were compared in mice for immunogenicity and protection against challenge with homologous and heterotypic influenza viruses. flu-ISCOMs but not subvirion vaccine fully protected mice against homologous virus challenge after one immunization as assessed by measurement of virus lung titers. The improved protection induced by flu-ISCOMs was associated with a 10-fold higher prechallenge serum hemagglutination inhibition titer. Furthermore, only flu-ISCOMs fully protected mice against mortality and reduced morbidity following challenge with an influenza virus of the serologically distinct H2N2 subtype. This cross-protection correlated with the induction of virus cross-reactive cytotoxic T lymphocytes that recognized a known major histocompatibility class I (H2-Kd)-restricted epitope within the hemagglutinin of influenza virus that is conserved among the H1 and H2 influenza virus subtypes. flu-ISCOMs may offer significant advantages over current commercial formulations as an improved influenza vaccine.
DOI: 10.1086/515285
PubMed: 9593011
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000383
Links to Exploration step
pubmed:9593011Curation
No country items
S. Sambhara<affiliation><nlm:affiliation>Department of Immunology, Research Center, Pasteur Mérieux Connaught Canada, Toronto.</nlm:affiliation><wicri:noCountry code="subField">Toronto</wicri:noCountry></affiliation>Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes.</title><author><name sortKey="Sambhara, S" sort="Sambhara, S" uniqKey="Sambhara S" first="S" last="Sambhara">S. Sambhara</name><affiliation><nlm:affiliation>Department of Immunology, Research Center, Pasteur Mérieux Connaught Canada, Toronto.</nlm:affiliation><wicri:noCountry code="subField">Toronto</wicri:noCountry></affiliation></author><author><name sortKey="Woods, S" sort="Woods, S" uniqKey="Woods S" first="S" last="Woods">S. Woods</name></author><author><name sortKey="Arpino, R" sort="Arpino, R" uniqKey="Arpino R" first="R" last="Arpino">R. Arpino</name></author><author><name sortKey="Kurichh, A" sort="Kurichh, A" uniqKey="Kurichh A" first="A" last="Kurichh">A. Kurichh</name></author><author><name sortKey="Tamane, A" sort="Tamane, A" uniqKey="Tamane A" first="A" last="Tamane">A. Tamane</name></author><author><name sortKey="Underdown, B" sort="Underdown, B" uniqKey="Underdown B" first="B" last="Underdown">B. Underdown</name></author><author><name sortKey="Klein, M" sort="Klein, M" uniqKey="Klein M" first="M" last="Klein">M. Klein</name></author><author><name sortKey="Lovgren Bengtsson, K" sort="Lovgren Bengtsson, K" uniqKey="Lovgren Bengtsson K" first="K" last="Lövgren Bengtsson">K. Lövgren Bengtsson</name></author><author><name sortKey="Morein, B" sort="Morein, B" uniqKey="Morein B" first="B" last="Morein">B. Morein</name></author><author><name sortKey="Burt, D" sort="Burt, D" uniqKey="Burt D" first="D" last="Burt">D. Burt</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1998">1998</date><idno type="RBID">pubmed:9593011</idno><idno type="pmid">9593011</idno><idno type="doi">10.1086/515285</idno><idno type="wicri:Area/PubMed/Corpus">000383</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000383</idno><idno type="wicri:Area/PubMed/Curation">000383</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000383</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes.</title><author><name sortKey="Sambhara, S" sort="Sambhara, S" uniqKey="Sambhara S" first="S" last="Sambhara">S. Sambhara</name><affiliation><nlm:affiliation>Department of Immunology, Research Center, Pasteur Mérieux Connaught Canada, Toronto.</nlm:affiliation><wicri:noCountry code="subField">Toronto</wicri:noCountry></affiliation></author><author><name sortKey="Woods, S" sort="Woods, S" uniqKey="Woods S" first="S" last="Woods">S. Woods</name></author><author><name sortKey="Arpino, R" sort="Arpino, R" uniqKey="Arpino R" first="R" last="Arpino">R. Arpino</name></author><author><name sortKey="Kurichh, A" sort="Kurichh, A" uniqKey="Kurichh A" first="A" last="Kurichh">A. Kurichh</name></author><author><name sortKey="Tamane, A" sort="Tamane, A" uniqKey="Tamane A" first="A" last="Tamane">A. Tamane</name></author><author><name sortKey="Underdown, B" sort="Underdown, B" uniqKey="Underdown B" first="B" last="Underdown">B. Underdown</name></author><author><name sortKey="Klein, M" sort="Klein, M" uniqKey="Klein M" first="M" last="Klein">M. Klein</name></author><author><name sortKey="Lovgren Bengtsson, K" sort="Lovgren Bengtsson, K" uniqKey="Lovgren Bengtsson K" first="K" last="Lövgren Bengtsson">K. Lövgren Bengtsson</name></author><author><name sortKey="Morein, B" sort="Morein, B" uniqKey="Morein B" first="B" last="Morein">B. Morein</name></author><author><name sortKey="Burt, D" sort="Burt, D" uniqKey="Burt D" first="D" last="Burt">D. Burt</name></author></analytic><series><title level="j">The Journal of infectious diseases</title><idno type="ISSN">0022-1899</idno><imprint><date when="1998" type="published">1998</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Cross Reactions</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>ISCOMs</term><term>Influenza A virus (classification)</term><term>Influenza A virus (immunology)</term><term>Influenza Vaccines</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Orthomyxoviridae Infections (immunology)</term><term>Orthomyxoviridae Infections (mortality)</term><term>Orthomyxoviridae Infections (prevention & control)</term><term>T-Lymphocytes, Cytotoxic (immunology)</term><term>Time Factors</term><term>Virion (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Complexes immunostimulants</term><term>Facteurs temps</term><term>Femelle</term><term>Infections à Orthomyxoviridae ()</term><term>Infections à Orthomyxoviridae (immunologie)</term><term>Infections à Orthomyxoviridae (mortalité)</term><term>Lymphocytes T cytotoxiques (immunologie)</term><term>Relation dose-effet des médicaments</term><term>Réactions croisées</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Vaccins antigrippaux</term><term>Virion (immunologie)</term><term>Virus de la grippe A ()</term><term>Virus de la grippe A (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>ISCOMs</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Influenza A virus</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Infections à Orthomyxoviridae</term><term>Lymphocytes T cytotoxiques</term><term>Virion</term><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A virus</term><term>Orthomyxoviridae Infections</term><term>T-Lymphocytes, Cytotoxic</term><term>Virion</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Infections à Orthomyxoviridae</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cross Reactions</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Complexes immunostimulants</term><term>Facteurs temps</term><term>Femelle</term><term>Infections à Orthomyxoviridae</term><term>Relation dose-effet des médicaments</term><term>Réactions croisées</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Vaccins antigrippaux</term><term>Virus de la grippe A</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Influenza immunostimulating complexes (flu-ISCOMs) and a monovalent subvirion vaccine prepared with an H1N1 strain of influenza virus were compared in mice for immunogenicity and protection against challenge with homologous and heterotypic influenza viruses. flu-ISCOMs but not subvirion vaccine fully protected mice against homologous virus challenge after one immunization as assessed by measurement of virus lung titers. The improved protection induced by flu-ISCOMs was associated with a 10-fold higher prechallenge serum hemagglutination inhibition titer. Furthermore, only flu-ISCOMs fully protected mice against mortality and reduced morbidity following challenge with an influenza virus of the serologically distinct H2N2 subtype. This cross-protection correlated with the induction of virus cross-reactive cytotoxic T lymphocytes that recognized a known major histocompatibility class I (H2-Kd)-restricted epitope within the hemagglutinin of influenza virus that is conserved among the H1 and H2 influenza virus subtypes. flu-ISCOMs may offer significant advantages over current commercial formulations as an improved influenza vaccine.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9593011</PMID><DateCompleted><Year>1998</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-1899</ISSN><JournalIssue CitedMedium="Print"><Volume>177</Volume><Issue>5</Issue><PubDate><Year>1998</Year><Month>May</Month></PubDate></JournalIssue><Title>The Journal of infectious diseases</Title><ISOAbbreviation>J. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes.</ArticleTitle><Pagination><MedlinePgn>1266-74</MedlinePgn></Pagination><Abstract><AbstractText>Influenza immunostimulating complexes (flu-ISCOMs) and a monovalent subvirion vaccine prepared with an H1N1 strain of influenza virus were compared in mice for immunogenicity and protection against challenge with homologous and heterotypic influenza viruses. flu-ISCOMs but not subvirion vaccine fully protected mice against homologous virus challenge after one immunization as assessed by measurement of virus lung titers. The improved protection induced by flu-ISCOMs was associated with a 10-fold higher prechallenge serum hemagglutination inhibition titer. Furthermore, only flu-ISCOMs fully protected mice against mortality and reduced morbidity following challenge with an influenza virus of the serologically distinct H2N2 subtype. This cross-protection correlated with the induction of virus cross-reactive cytotoxic T lymphocytes that recognized a known major histocompatibility class I (H2-Kd)-restricted epitope within the hemagglutinin of influenza virus that is conserved among the H1 and H2 influenza virus subtypes. flu-ISCOMs may offer significant advantages over current commercial formulations as an improved influenza vaccine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sambhara</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Immunology, Research Center, Pasteur Mérieux Connaught Canada, Toronto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woods</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Arpino</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kurichh</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tamane</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Underdown</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lövgren Bengtsson</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Morein</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Burt</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Infect Dis</MedlineTA><NlmUniqueID>0413675</NlmUniqueID><ISSNLinking>0022-1899</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016882">ISCOMs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016882" MajorTopicYN="Y">ISCOMs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="Y">Influenza A virus</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014771" MajorTopicYN="N">Virion</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>5</Month><Day>21</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>5</Month><Day>21</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9593011</ArticleId><ArticleId IdType="doi">10.1086/515285</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000383 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000383 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:9593011
|texte= Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:9593011" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |